SAN FRANCISCO -- Oncoceutics, a start-up oncology company based in Pennsylvania launched today. The company’s main focus is the development of small molecule compounds to correct mutational defects in p53, the most common protein mutation in human cancers. The research stems from Wafik El-Deiry, a physician-scientist at the University of Pennsylvania.
The principal founders of Oncoceutics are Wafik El-Deiry, M.D., Ph.D., Wolfgang Oster, M.D., Ph.D., Lee Schalop, M.D., and The University of Pennsylvania.
For more information please visit, oncoceutics.com.
